WILMINGTON, Del., June 16, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector. HOPE Therape ...

WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx, today announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16–17, 2025. HOPE Therapeutics, Inc. (PRNewsfoto/NRx Pharmaceut ...

In April 2025, the FDA granted a waiver of the $4.3 million NDA fee under the PDUFA, recognizing both the product's public health value and NRx's qualification under small business provisions. NRX-100 was previously granted Fast Track Designation in a protocol with NRX-101. With regulatory filings underway, patent protection sought through 2045, and a growing body of clinical and technical validation, NRx believes NRX- 100 is well-positioned to become a next-generation standard in both the emerging mental h ...

财务数据关键指标变化 - 2025年第一季度净亏损550万美元，较2024年同期的650万美元有所收窄；运营亏损380万美元，较2024年同期的600万美元收窄；研发和行政费用分别为80万美元和290万美元，较2024年同期的170万美元和430万美元减少[21] - 2025年1月通过可转换债务和股权融资共筹集890万美元，增强了资产负债表[18] - 截至2025年3月31日，公司拥有约550万美元的现金及现金等价物[21] 业务线新药进展 - 公司计划在2025年第二季度完成NRX - 100的新药申请（NDA）提交，FDA豁免了430万美元的NDA提交费用[4][8] - NRX - 100的美国专利申请已在2025年5月提交，若获批，专利保护期至2045年[10] - NRX - 101有望在2025年底前获得加速批准的NDA提交，预计PDUFA日期在2025年[4][13] 业务线收购与收入预估 - HOPE Therapeutics计划收购的Kadima、Dura Medical和Neurospa TMS预计带来约1500万美元的前瞻性预估收入[4][16] - HOPE已与另外四家临床实体谈判，预计带来约2000万美元的潜在预估收入[4] - HOPE执行了总计1030万美元的收购资本融资协议，包括250万美元的战略投资和780万美元的债务融资[4][19][20] - 公司目标是到2025年底通过收购诊所网络实现总计1亿美元的前瞻性预估收入[17]

NRx Pharmaceuticals (NRXP) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Matthew Duffy - Chief Business Officer & Co-CEO of Hope TherapeuticsJonathan Javitt - Founder, Chairman, Chief Scientist & Co-CEO of Hope TherapeuticsMichael Abrams - CFO Conference Call Participants Thomas Shrader - MD & Healthcare AnalystEdward Woo - Director of Research & Senior Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter twenty twenty five Earning ...

NRx Pharmaceuticals (NRXP) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter twenty twenty five Earnings Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call, you require immediate assistance, please press 0 for the operator. This call is being recorded on Thursday, 05/15/2025. I would now like to turn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38302 NRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Em ...

Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to t ...

Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term  MIAMI, May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiar ...

收购交易 - HOPE Therapeutics与Kadima Neuropsychiatry Institute签署最终收购协议，后者将成为HOPE旗下诊所的临床治疗模式标杆[1] - Kadima是加州旗舰级介入精神病学诊所，率先将氯胺酮治疗从中枢神经系统(CNS)学术研究引入临床实践，提供自杀性抑郁症、PTSD等全方位治疗[2] - 交易完成后Kadima创始人David Feifel博士将加入HOPE担任首席医疗创新官(CMIO)，其在介入精神病学领域具有全国影响力并主导多项CNS临床试验[3] 战略意义 - 此次收购标志着HOPE重塑精神医疗服务的战略关键节点，将加速建设整合尖端科学与社区护理的诊所网络[4] - Kadima作为全国领先的CNS和致幻剂研究基地，曾主导该领域几乎所有重大临床试验[6] - 收购预计将提升NRx和HOPE的营收及EBITDA[6] 标的公司概况 - Kadima目前实现盈利且预计持续增长，提供氯胺酮、Spravato、经颅磁刺激(TMS)等创新疗法[2] - 诊所创始人Feifel博士是美国神经药理学学院当选成员，入选"全美最佳医生"并担任临床TMS学会董事会成员[3] 母公司业务进展 - NRx Pharmaceuticals正在基于NMDA平台开发NRX-101(治疗自杀性双相抑郁症的突破性疗法)和NRX-100(静脉注射氯胺酮)[5][6] - NRX-100已获FDA快速通道认定，用于治疗急性自杀倾向患者，并提交新药申请[6][7] - HOPE Therapeutics正在建设介入精神病学诊所网络，结合数字治疗平台增强NMDA靶向药物疗效[8]